Market Overview

UPDATE: Jefferies Raises PT on Bristol-Myers Squibb on Positive Outlook

Share:
Related BMY
Tuesday Morning Movers: Microsoft, Procter & Gamble Tumble Following Earnings
UPDATE: Bristol-Meyers Squibb Posts Upbeat Q4 Results, Issues Downbeat Forecast
Poor Pipeline Productivity Has Left Roche More Vulnerable (Seeking Alpha)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY), and raised the price target from $41.00 to $45.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Bristol-Myers Squibb Co. closed on Tuesday at $40.83.

Latest Ratings for BMY

DateFirmActionFromTo
Jan 2015BarclaysMaintainsEqual-weight
Jan 2015JefferiesMaintainsHold
Dec 2014JefferiesMaintainsHold

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMY)

Around the Web, We're Loving...

Get Benzinga's Newsletters